AVRO News and Press, AVROBIO Inc. From 03/23/23

2023-03-23 07:56:54 ET AVROBIO press release ( NASDAQ: AVRO ): Q4 GAAP EPS of -$0.57 misses by $0.12 . As of Dec. 31, 2022, AVROBIO had $92.6 million in cash and cash equivalents, as compared to $189.6 million in cash and cash equivalents as of Dec. 31, 2021. Based on ...

Following positive regulatory feedback, plan to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment Patient dosing completed in collaborator-sponsored Phase 1/2 clinical trial for cystinosis; plan to...

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in a panel titled “Orphan Neuro Corporate Panel” at Cowen...

Sangamo Therapeutics ( NASDAQ: SGMO ) added ~11% on Monday after Wedbush Securities upgraded the genomic medicine company to Outperform from Neutral, noting a recent data readout for the company's Fabry disease candidate ST-920. Announcing updated data from its Phase 1/2 STAAR cli...

Four platform presentations and two posters with data on AVROBIO’s lysosomal disorder programs to be presented AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that updat...

Avrobio Inc. ( NASDAQ: AVRO ) soared 23% amid a report that the company is exploring a possible sale after an approach from Novartis ( NVS ). A takeover for the company may be valued at more than quadruple its market price before it popped on the takeover speculation, accordin...

New compelling clinical data from first-ever Gaucher disease type 3 (GD3) patient and four Gaucher disease type 1 (GD1) patients dosed with investigational AVR-RD-02 Data from first pediatric GD3 patient, the more severe, progressive form of Gaucher disease, show biochemical correction an...

Webcast on Wednesday, Dec. 7, 2022, at 8 am ET AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it will host a virtual Gaucher Disease Program Update...

AVROBIO press release ( NASDAQ: AVRO ): Q3 GAAP EPS of -$0.52 beats by $0.01 . As of September 30, 2022, AVROBIO had $116.0 million in cash and cash equivalents, as compared to $189.6 million in cash and cash equivalents as of December 31, 2021. Based on AVROBIO ...

Patient dosing completed in collaborator-sponsored Phase 1/2 clinical trial for cystinosis Rare pediatric disease designations received for Gaucher disease and cystinosis investigational gene therapies Comprehensive Gaucher disease program update planned for Wednesday,...